Management of hepatitis C virus infection in childhood

array:24 ["pii" => "S1665268119317326" "issn" => "16652681" "doi" => "10.1016/S1665-2681(19)31732-6" "estado" => "S300" "fechaPublicacion" => "2010-01-01" "aid" => "71394" "copyright" => "Fundación Clínica Médica Sur, A.C." "copyrightAnyo" => "2010" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2010;9 Supl 1:S98-S102" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 52 "formatos" => array:3 [ "EPUB" => 12 "HTML" => 20 "PDF" => 20 ] ] "itemSiguiente" => array:19 [ "pii" => "S1665268119317338" "issn" => "16652681" "doi" => "10.1016/S1665-2681(19)31733-8" "estado" => "S300" "fechaPublicacion" => "2010-01-01" "aid" => "71395" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2010;9 Supl 1:S103-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 55 "formatos" => array:3 [ "EPUB" => 16 "HTML" => 17 "PDF" => 22 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Treatment of HCV infected patients and renal disease" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S103" "paginaFinal" => "S106" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "David Kershenobich" "autores" => array:1 [ 0 => array:2 [ "nombre" => "David" "apellidos" => "Kershenobich" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119317338?idApp=UINPBA00004N" "url" => "/16652681/00000009000000S1/v1_201906221034/S1665268119317338/v1_201906221034/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1665268119317314" "issn" => "16652681" "doi" => "10.1016/S1665-2681(19)31731-4" "estado" => "S300" "fechaPublicacion" => "2010-01-01" "aid" => "71393" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2010;9 Supl 1:S92-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 56 "formatos" => array:3 [ "EPUB" => 10 "HTML" => 21 "PDF" => 25 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "The management of HCV-infected pregnant women" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S92" "paginaFinal" => "S97" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Guillermo Valladares, Maria H. Sjogren, Alfonso Chacaltana" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Guillermo" "apellidos" => "Valladares" ] 1 => array:2 [ "nombre" => "Maria H." "apellidos" => "Sjogren" ] 2 => array:2 [ "nombre" => "Alfonso" "apellidos" => "Chacaltana" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119317314?idApp=UINPBA00004N" "url" => "/16652681/00000009000000S1/v1_201906221034/S1665268119317314/v1_201906221034/en/main.assets" ] "en" => array:16 [ "idiomaDefecto" => true "titulo" => "Management of hepatitis C virus infection in childhood" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "S98" "paginaFinal" => "S102" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Marcela Galoppo, Cristina Galoppo" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Marcela" "apellidos" => "Galoppo" "email" => array:2 [ 0 => "mgaloppo@hotmail.com" 1 => "crisgaloppo@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "aff1" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor1" ] ] ] 1 => array:3 [ "nombre" => "Cristina" "apellidos" => "Galoppo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "aff1" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:3 [ "entidad" => "Pediatric Hepatologist" "etiqueta" => "*" "identificador" => "aff1" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "*" "correspondencia" => "Correspondence and reprint request:" ] ] ] ] "textoCompleto" => "IntroductionInfection with hepatitis C virus (HCV) is a worldwide health problem with more than 170 million infected individuals.<a class="elsevierStyleCrossRef" href="#bib0005">1</a>,<a class="elsevierStyleCrossRef" href="#bib0010">2</a> There is geographic variation in the incidence and prevalence of this infection.HCV antibodies in children are between 0.2% and 0.4%, with an age-dependent increase in seropreva-lence (0.2% for children aged 6-11 years and 0.4% for children aged 12-19 years).<a class="elsevierStyleCrossRef" href="#bib0015">3</a> Since 1992 almost all infections occurred through vertical transmission from an infected mother to her newborn infant.<a class="elsevierStyleCrossRef" href="#bib0020">4</a>A recent report of Italy showed 40% reduction in the number of infected children seen from 2000 to 2004 by comparison with the previous 5 years. The low prevalence of HCV infection in children can be explained by the disappearance of post transfusion hepatitis in developed countries and the low efficacy of mother-to-child transmission, which has become the principal source of infection in the pediatric set-ting.<a class="elsevierStyleCrossRefs" href="#bib0025">5</a>-<a class="elsevierStyleCrossRef" href="#bib0035">7</a>Natural history of HCV infection in children is not yet well defined; most children are asymptomatic and may remain so for decades. Diagnosis is generally made screening risk factor patients, elevated aminotransferases in routine tests and household HCV infected adults.<a class="elsevierStyleCrossRef" href="#bib0040">8</a>Treatment strategies in adults have had a significant impact on the management of children with HCV chronic infection. All efforts now are towards to early diagnosis, safety and efficacy treatment.Epidemiology and Risk of TransmissionAfter blood donor screening began in the 1990’s, the risk of contracting HCV from blood and derivatives became extremely low in developed countries, in-travenous drug abuse and high-risk sexual behavior are maintaining the reservoir of infection in adults and groups of adolescents. Transmission through in-fected blood products, however, remains a risk in countries where strict recommendations for screening blood products are not reliably adhered to. Horizontal transmission for family members is uncommon.<a class="elsevierStyleCrossRef" href="#bib0020">4</a>In children vertical transmission is responsible for most “new infections”, however, has an efficiency of only about 5%.<a class="elsevierStyleCrossRefs" href="#bib0030">6</a>-<a class="elsevierStyleCrossRef" href="#bib0040">8</a>Risk of maternal-infant transmission is increased (up to 22%) by level of maternal HCV viral load such as HIV co infection.<a class="elsevierStyleCrossRef" href="#bib0040">8</a>-<a class="elsevierStyleCrossRef" href="#bib0045">9</a>Vertical transmission is almost always confined to women who have detectable HCV RNA. There is an extremely low risk of transmission with undetec-table or intermittent viremia, even though the risk of infection in this clinical situation is as low as 0.3%.<a class="elsevierStyleCrossRef" href="#bib0045">9</a>-<a class="elsevierStyleCrossRef" href="#bib0050">10</a>Presumably, both intrauterine and intrapartum infections occur. The mode of delivery does not affect risk of HCV transmission. Membrane ruptures longer than six hours and internal fetal monitoring were associated with an increased risk of transmission. Current recommendations are that women with HCV without HIV co-infection can be advised to breast feed.<a class="elsevierStyleCrossRef" href="#bib0040">8</a>,<a class="elsevierStyleCrossRefs" href="#bib0045">9</a>,<a class="elsevierStyleCrossRef" href="#bib0055">11</a>,<a class="elsevierStyleCrossRef" href="#bib0060">12</a>Recent studies showed that girls were twice as likely to be infected as boys. This finding, may reflects differences between males and females in hormonal or genetic susceptibility or immunological response to infections.<a class="elsevierStyleCrossRefs" href="#bib0045">9</a>-<a class="elsevierStyleCrossRef" href="#bib0065">13</a>Diagnoses of HCV infection in exposed infants is hampered by passive transfer of maternal antibodies during pregnancy persisting up to 13 to 18 months of life.<a class="elsevierStyleCrossRef" href="#bib0070">14</a> HCVRNA polymerase chain reaction (PCR) testing is highly specific, but its sensitivity is low at birth and in the first days of life (22%) while it increases at one month of age and thereafter (> 75%).<a class="elsevierStyleCrossRefs" href="#bib0045">9</a>-<a class="elsevierStyleCrossRef" href="#bib0075">15</a>A child born to a seropositive mother is conside-rer to be infected if serum HCVRNA is detectable in at least two separate determinations between 2-6 months and whit persistence of anti-HCV antibodies after the first year of life. Chronic infection is defined as the persistence of HCV RNA for at least six months and resolution is determined by the persistent disappearance of HCVRNA.Natural History and DiagnosisMost infected individuals (60-80%), regardless of their age at infection, become chronically infected with HCV.<a class="elsevierStyleCrossRef" href="#bib0080">16</a>Spontaneous resolution in children appears to be infrequent: in three large series, including vertical and horizontal acquisition, HCV clearance occurred in 5.6-10%,<a class="elsevierStyleCrossRefs" href="#bib0025">5</a>,<a class="elsevierStyleCrossRefs" href="#bib0045">9</a>,<a class="elsevierStyleCrossRef" href="#bib0085">17</a> children infected with genotype 3 (81% of whom were vertically infected) had the highest rate of viral clearance (22%) compared to other genotypes.<a class="elsevierStyleCrossRefs" href="#bib0025">5</a>,<a class="elsevierStyleCrossRef" href="#bib0045">9</a>In 266 vertically HCV infected children, 17% showed viral clearance by 2, 24% by 3, and 25% by 5 years of age (median age 14. 9 m).<a class="elsevierStyleCrossRef" href="#bib0085">17</a>Transfusion acquired infection have a higher chance of spontaneous clearance than vertical acquisition. HCV genotype, viral load and immunoto-lerance in young infants, were proposed to influence viral resolution.<a class="elsevierStyleCrossRefs" href="#bib0045">9</a>-<a class="elsevierStyleCrossRef" href="#bib0090">18</a>Once chronicity is established, such as in older children, serological and histological features seem to be independent of the source and time of infec-tion.<a class="elsevierStyleCrossRef" href="#bib0095">19</a> Illness is generally asymptomatic and characterized by a bening course during the first two decades of life. Advanced liver disease is rare during childhood and there are no reports of acute liver failure in HCV pediatric infected patient.<a class="elsevierStyleCrossRef" href="#bib0090">18</a> Clinical symptoms are mild and nonspecific in only 20% of cases during early childhood. Hepatomegaly is present in 10% of infected children.HCV-associated cryoglobulinemia, vasculitis and porphyria cutanea tarda are not reported in chil-dren.<a class="elsevierStyleCrossRef" href="#bib0100">20</a>Aminotransferases remains usually normal or mildly abnormal levels but it is not a reliable indicator of abscense of hepatic injury.<a class="elsevierStyleCrossRefs" href="#bib0040">8</a>,<a class="elsevierStyleCrossRef" href="#bib0080">16</a>,<a class="elsevierStyleCrossRefs" href="#bib0085">17</a>,<a class="elsevierStyleCrossRef" href="#bib0105">21</a>Positive HCV antibody implicate that patient has been exposed to the virus (EIA test). Anti-HCV antibodies may be undetectable during first few weeks after HCV exposure or in immunocompromised pa-tients.<a class="elsevierStyleCrossRef" href="#bib0090">18</a>To discriminate between active or resolved HCV viral infection it is necessary to perform HCV RNA (PCR). HCV RNA PCR may be intermittently negative.HCV genotype and HCV-RNA viral load provide useful information for predicting response to therapy. HCV genotype is also used to determine the length of therapy.<a class="elsevierStyleCrossRefs" href="#bib0040">8</a>-<a class="elsevierStyleCrossRef" href="#bib0090">18</a>Liver biopsy assess degree of liver injury and exclude concurrent diseases specially in children with normal transaminases who are being considered for treatment.<a class="elsevierStyleCrossRefs" href="#bib0040">8</a>-<a class="elsevierStyleCrossRef" href="#bib0090">18</a> Histological picture is similar to those of adults. Necrotic inflammation and fibrosis are usually milder, though liver damage is greater in older patients and progression to cirrhosis has been noted.<a class="elsevierStyleCrossRefs" href="#bib0035">7</a>,<a class="elsevierStyleCrossRefs" href="#bib0045">9</a>,<a class="elsevierStyleCrossRef" href="#bib0090">18</a>,<a class="elsevierStyleCrossRef" href="#bib0095">19</a>,<a class="elsevierStyleCrossRefs" href="#bib0100">20</a>,<a class="elsevierStyleCrossRef" href="#bib0110">22</a>TreatmentHCV chronic infection is slow progressive in childhood therefore’ there is no uniform consensus about timing for treatment. Progression of fibrosis seems to be a function of infection duration’ when no other risk factors for liver damage are present. HCV cirrhosis and its complications in adulthood and universal recurrence in post transplant recipients justify medical decision in favor of treatment. Therefore, children are ideal candidates for treatment. The shorter the duration of infection with mild histological disease, the better the response to treatment.<a class="elsevierStyleCrossRef" href="#bib0040">8</a>,<a class="elsevierStyleCrossRefs" href="#bib0045">9</a>,<a class="elsevierStyleCrossRefs" href="#bib0090">18</a>,<a class="elsevierStyleCrossRef" href="#bib0100">20</a>,<a class="elsevierStyleCrossRef" href="#bib0105">21</a>A review of published trials with Interferon (IFN) monotherapy in 105 children showed average an end-of-treatment response (ETR) of 54% and sustained virological response (SVR) of 36%. The SVR in genotype 1 was 27% versus 70% for non genotype 1 (p: 0.001). The SVR rates were higher than those reported in adults.<a class="elsevierStyleCrossRef" href="#bib0115">23</a>Different trials with combination therapy were done and others are in progress <a class="elsevierStyleCrossRef" href="#t0005">(Table 1)</a>.<elsevierMultimedia ident="t0005"></elsevierMultimedia>Primary Goal of TreatmentClearance viral infection (HCV RNA non detectable in serum), regression or delay in liver fibrosis, prevention of chronic liver disease and development of HCC and improve quality of life.Benefits of treatment are not restricted to biochemical, histologic or virologic response: quality of life, risk of hepatocellular carcinoma, and mortality risk may be favorably affected by treatment, even in the absence of sustained viral response.<a class="elsevierStyleCrossRefs" href="#bib0020">4</a>,<a class="elsevierStyleCrossRefs" href="#bib0090">18</a>,<a class="elsevierStyleCrossRef" href="#bib0120">24</a>,<a class="elsevierStyleCrossRef" href="#bib0125">25</a>Considering TreatmentIFN alfa is recognized as the drug approved for hepatitis C treatment in pediatric population. As in adults, combination therapy with IFNα or pegylated IFNα and ribavirin in children under clinical trials, support its efficacy in sustained virological response (SVR) compared with IFNα alone. Recently, the US FDA and EMEA have approved combined pegylated-IFNα2b plus ribavirin treatment for children.<a class="elsevierStyleCrossRef" href="#bib0100">20</a> Principal advantage of PEG-IFNα is the extended serum half-life conferred by pegylation of the IFN molecule, which confers a once-weekly administration and improved efficacy and a safety profile similar to that of IFNα.<a class="elsevierStyleCrossRef" href="#bib0090">18</a>Treatment should be considered in children between 3 to 18 years old, anti HCV (+), HCVRNA (+) for at least 6 months and normal or abnormal ALT.Patients are excluded if they have comorbid medical conditions that could compromise the safety, efficacy and tolerability of drugs.<a class="elsevierStyleCrossRefs" href="#bib0020">4</a>,<a class="elsevierStyleCrossRef" href="#bib0100">20</a>Liver biopsy remains the gold standard for assessing the severity of inflammation and fibrosis, and rule out concurrent diseases particularly in children whit normal liver tests. Inflammation and fibrosis are less common than in adults but significant fibro-sis and cirrhosis may develop during childhood. In a series of 112 pediatric patients with chronic hepatitis C the degree of fibrosis correlated with age and duration of infection.<a class="elsevierStyleCrossRef" href="#bib0135">27</a>,<a class="elsevierStyleCrossRef" href="#bib0140">28</a>There are different opinions about performing liver biopsy in genotypes 2 and 3 whose sustained vi-rological response rates exceed 80%.<a class="elsevierStyleCrossRefs" href="#bib0035">7</a>,<a class="elsevierStyleCrossRefs" href="#bib0090">18</a>,<a class="elsevierStyleCrossRef" href="#bib0130">26</a>HCV genotype should be identify to establish treatment duration and probability of response. For genotypes 1 and 4, therapy is recommended for at least 48 weeks, overall SVR is 50%. Genotypes 2 and 3 should be treated only for 24 weeks; overall SVR is 83-100%.<a class="elsevierStyleCrossRefs" href="#bib0090">18</a>-<a class="elsevierStyleCrossRef" href="#bib0100">20</a>Viral load is necessary to evaluate virological response during treatment.Treatment objective is clearance of HCVRNA below the detection limit of PCR technique employed (30-50IU/mL). Then, therapy should continue in order to eradicate infection in the liver.Treatment Schedule and MonitoringThe dose of IFNα monotherapy is 3 MIU/m<a class="elsevierStyleCrossRef" href="#bib0010">2</a> sub-cutaneously 3 times a week.<a class="elsevierStyleCrossRefs" href="#bib0040">8</a>,<a class="elsevierStyleCrossRef" href="#bib0115">23</a>PEG-IFNα-2b (60 μg/m<a class="elsevierStyleCrossRef" href="#bib0010">2</a>/week or 1-1.5 μg/kg/wk) or α2a (100 μg/m<a class="elsevierStyleCrossRef" href="#bib0010">2</a>/week) subcutaneously plus Riba-virina (15 mg/kg/day) twice orally is used in combination therapy.<a class="elsevierStyleCrossRefs" href="#bib0090">18</a>,<a class="elsevierStyleCrossRefs" href="#bib0100">20</a>,<a class="elsevierStyleCrossRefs" href="#bib0115">23</a>,<a class="elsevierStyleCrossRefs" href="#bib0130">26</a>,<a class="elsevierStyleCrossRef" href="#bib0145">29</a>Adverse events are common during treatment, particularly transient “flu-like syndrome”, leukope-nia and neutropenia related to IFN. Although rare, depression and suicidal ideation attempt occurs in treated children. Antithyroid antibodies are common and clinical thyroid disease occurs but rarely becomes permanent.<a class="elsevierStyleCrossRefs" href="#bib0020">4</a>,<a class="elsevierStyleCrossRefs" href="#bib0090">18</a>,<a class="elsevierStyleCrossRefs" href="#bib0100">20</a>,<a class="elsevierStyleCrossRefs" href="#bib0130">26</a>,<a class="elsevierStyleCrossRef" href="#bib0145">29</a>The most common adverse effect of ribavirin is a reversible hemolytic anemia. Ribavirin is also known to be teratogenic.<a class="elsevierStyleCrossRefs" href="#bib0020">4</a>,<a class="elsevierStyleCrossRefs" href="#bib0090">18</a>,<a class="elsevierStyleCrossRefs" href="#bib0100">20</a>,<a class="elsevierStyleCrossRefs" href="#bib0130">26</a>,<a class="elsevierStyleCrossRef" href="#bib0145">29</a>Liver, hematology, thyroid and other routine tests should be periodically done in order to detect adverse events for evaluate eventually reduction or interruption medication. HCV RNA titers are measured at 4, 12, 24, 36 and 48 weeks, and every 12 weeks for another 6 months after the end of treatment.Diagnosis and treatment strategies in children should be prescribe and supervise by pediatric hepa-tologist.<a class="elsevierStyleCrossRef" href="#bib0040">8</a>" "textoCompletoSecciones" => array:1 [ "secciones" => array:10 [ 0 => array:3 [ "identificador" => "xres1210341" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abs0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1126758" "titulo" => "Key words" ] 2 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 3 => array:2 [ "identificador" => "sec0010" "titulo" => "Epidemiology and Risk of Transmission" ] 4 => array:2 [ "identificador" => "sec0015" "titulo" => "Natural History and Diagnosis" ] 5 => array:2 [ "identificador" => "sec0020" "titulo" => "Treatment" ] 6 => array:2 [ "identificador" => "sec0025" "titulo" => "Primary Goal of Treatment" ] 7 => array:2 [ "identificador" => "sec0030" "titulo" => "Considering Treatment" ] 8 => array:2 [ "identificador" => "sec0035" "titulo" => "Treatment Schedule and Monitoring" ] 9 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2010-03-20" "fechaAceptado" => "2010-04-20" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Key words" "identificador" => "xpalclavsec1126758" "palabras" => array:6 [ 0 => "Children" 1 => "Chronic hepatitis C" 2 => "Hepatitis C virus" 3 => "IFN" 4 => "Pegylated IFN" 5 => "Ribavirin" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "Infection with hepatitis C virus (HCV) is a worldwide health problem with more than 170 million infected individuals. In children, since 1992 almost all infections occurred through vertical transmission from an infected mother to her newborn infant. Natural history of HCV infection in children is not yet well defined, most children are asymptomatic and may remain so for decades. Most infected individuals (60-80%), regardless of their age at infection, become chronically infected with HCV. Spontaneous resolution in children appears to be infrequent. Positive HCV antibody implicate that patient has been exposed to the virus (EIA test). To discriminate between active or resolved HCV viral infection it is necessary to perform HCV RNA (PCR). Liver biopsy assess degree of liver injury and exclude concurrent diseases. HCV chronic infection is slow progressive in childhood. Progression of fibrosis seems to be a function of infection duration. Treatment objective is clearance of HCVRNA. IFNα is recognized as the drug approved for hepatitis C treatment in pediatric population. Combination therapy with IFNα or pegylated IFNα plus ribavirin is recently approved by US FDA and EMEA and clinical trials are in progress." ] ] "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "t0005" "etiqueta" => "Table 1." "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "HCV = hepatitis C virus; IFN = interferon; PEGIFN = pegylated interferon." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="middle" scope="col">Study \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="3" align="center" valign="middle" scope="col">Sustained response<a class="elsevierStyleCrossRef" href="#t1fn2">**</a> (%)</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col">N° Studied<a class="elsevierStyleCrossRef" href="#t1fn1">*</a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col">Treatment regimen \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col">All Types \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col">HCV type 1 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col">HCV type 2/3 \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">González-Peralta, et al. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">IFN-ribavirin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">64 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">40 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">100 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">Strickland, et al. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">IFN-ribavirin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">N/A <a class="elsevierStyleCrossRef" href="#t1fn3">***</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">Bruix and Sherman \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">41 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">IFN-ribavirin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">61 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">53 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">100 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">Peters and Terrault \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">118 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">IFN-ribavirin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">36 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">84 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">Sasaki, et al. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">PEGIFN \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">38 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">38 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">N/A \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">Ni, et al. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">59 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">PEGIFN-ribavirin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">59 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">100 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">lorio, et al. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">PEGIFN-ribavirin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">100 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">Fried, et al. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">107 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">PEGIFN-ribavirin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">65<a class="elsevierStyleCrossRef" href="#t1fn3">***</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">53<a class="elsevierStyleCrossRef" href="#t1fn4">****</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">93<a class="elsevierStyleCrossRef" href="#t1fn4">****</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">Di Bisceglie, et al. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">55 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">PEGIFN-ribavirin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">53 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">47<a class="elsevierStyleCrossRef" href="#t1fn4">****</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">80<a class="elsevierStyleCrossRef" href="#t1fn4">****</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">59 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">PEGIFN-alone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">18<a class="elsevierStyleCrossRef" href="#t1fn4">****</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">36<a class="elsevierStyleCrossRef" href="#t1fn4">****</a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">Jara, et al.<a class="elsevierStyleCrossRef" href="#bib0150">30</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">PEGIFN-ribavirin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">44 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">100 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">Wirth, et al.<a class="elsevierStyleCrossRef" href="#bib0155">31</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">107 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">PEGIFN-ribavirin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">65 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">53 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">93 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2066308.png" ] ] ] "notaPie" => array:4 [ 0 => array:3 [ "identificador" => "t1fn1" "etiqueta" => "*" "nota" => "Number of HCV-infected patients treated in the studies cited." ] 1 => array:3 [ "identificador" => "t1fn2" "etiqueta" => "**" "nota" => "Undetectable serum HCV RNA 6 months after stopping treatment." ] 2 => array:3 [ "identificador" => "t1fn3" "etiqueta" => "***" "nota" => "Sustained response was noted in 4 of 5 (80%) of enrolled children with HCV genotype 4." ] 3 => array:3 [ "identificador" => "t1fn4" "etiqueta" => "****" "nota" => "Only percentages presented in preliminary report (abstract)." ] ] ] "descripcion" => array:1 [ "en" => "Selected Treatment trials in children with chronic HCV infection.(18 modif)" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bs0005" "bibliografiaReferencia" => array:31 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Global epidemiology of Hepatitis C virus Infection." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Shepard CW" 1 => "Finelli L" 2 => "Alter MJ" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Lancet Infect Dis" "fecha" => "2005" "volumen" => "5" "paginaInicial" => "556" "paginaFinal" => "558" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium." "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "World Health Organization.Global Surveillance an Control of Hepatitis C." "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Viral Hepatitis" "fecha" => "1999" "volumen" => "6" "paginaInicial" => "35" "paginaFinal" => "47" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The prevalence of hepatitis C virus infection in the United States, 1988-1994." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Alter MD" 1 => "Kruszon-Moran D" 2 => "Nainan OV" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199908193410802" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1999" "volumen" => "341" "paginaInicial" => "556" "paginaFinal" => "562" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10451460" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management Strategies for Hepatitis C Virus Infection in Children." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Davison SM" 1 => "Kelly DA" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Pediatr Drugs" "fecha" => "2008" "volumen" => "10" "numero" => "6" "paginaInicial" => "357" "paginaFinal" => "365" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatitis C virus (HCV genotypes in 373 Italian children with HCV infection: changing distribution and correlation with clinical features and outcome." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Bortolotti F" 1 => "Resti M" 2 => "Marcellini M" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/gut.2004.053744" "Revista" => array:7 [ "tituloSerie" => "Gut" "fecha" => "2005" "volumen" => "54" "paginaInicial" => "852" "paginaFinal" => "857" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15888796" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0211139X17301270" "estado" => "S300" "issn" => "0211139X" ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Italian Observatory for HCV Infection and Hepatitis C in Children. Epidemiological profile of 806 Italian Children with hepatitis C virus infection over a 15-year period." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Bortolotti F" 1 => "Jorio R" 2 => "Resti M" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2006.12.014" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2007" "volumen" => "46" "paginaInicial" => "783" "paginaFinal" => "790" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17321633" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chronic viral hepatitis in children: any role for the pathologist?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Guido M" 1 => "Bortolotti F" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/gut.2007.139410" "Revista" => array:7 [ "tituloSerie" => "Gut" "fecha" => "2008" "volumen" => "57" "paginaInicial" => "873" "paginaFinal" => "877" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18559378" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S147330991730405X" "estado" => "S300" "issn" => "14733099" ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Organizado por la Aso-ciación Argentina para el Estudio de las Enfermedades del Higado (AAEEH)." "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Consenso Argentino de Hepatitis C." "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Buenos Aires" "fecha" => "2007" "paginaInicial" => "53" "paginaFinal" => "69" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Perinatal hepatitis C virus infection: Diagnosis and management." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Davison SM" 1 => "Mieli-Vergani G" 2 => "Sira J" 3 => "Kelly DA" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/adc.2005.081877" "Revista" => array:6 [ "tituloSerie" => "Arch Dis Child" "fecha" => "2006" "volumen" => "91" "paginaInicial" => "781" "paginaFinal" => "785" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16923861" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Committee of Hepatology of the Italian Society of Pediatric Gastroenteroly and Hepatology. Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Resti M" 1 => "Bortolotti F" 2 => "Vajro P" 3 => "Maggiore G" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Dig Liver Dis" "fecha" => "2003" "volumen" => "35" "numero" => "7" "paginaInicial" => "453" "paginaFinal" => "457" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12870728" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of mode and delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus." "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "European Pediatric Hepatitis C Virus Network." "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Br J Obstet Ginaecol" "fecha" => "2001" "volumen" => "108" "paginaInicial" => "371" "paginaFinal" => "377" "itemHostRev" => array:3 [ "pii" => "S0211139X16301354" "estado" => "S300" "issn" => "0211139X" ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk Factors for prenatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Mast EE" 1 => "Hwang LY" 2 => "Seto DSY" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/497701" "Revista" => array:7 [ "tituloSerie" => "J Infect Dis" "fecha" => "2005" "volumen" => "192" "paginaInicial" => "1880" "paginaFinal" => "1889" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16267758" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S138665321830074X" "estado" => "S300" "issn" => "13866532" ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A significant sex-but not elective caesarean section-effect on mother-to-child-transmission of hepatitis C virus infection." "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "European Pediatric Hepatitis C Virus Network." "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/497695" "Revista" => array:6 [ "tituloSerie" => "J Infect Dis" "fecha" => "2005" "volumen" => "192" "paginaInicial" => "1872" "paginaFinal" => "1879" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16267757" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "European Pediatric HCV Network. Excluding hepatitis C virus (HCV) infection by serology in young infants of HCV-infected mothers." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "England K" 1 => "Pembrey L" 2 => "Tovo TA" 3 => "Newell ML" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1651-2227.2005.tb01916.x" "Revista" => array:7 [ "tituloSerie" => "Acta Paediatr" "fecha" => "2005" "volumen" => "94" "paginaInicial" => "444" "paginaFinal" => "450" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16092459" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0264410X16301700" "estado" => "S300" "issn" => "0264410X" ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Accuracy of HCV-RNA PCR Test for Diagnosis of Exclusion of Vertically Acquired HCV Infection." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Polywka S" 1 => "Pembrey L" 2 => "Tovo PA" 3 => "Newell ML" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/jmv.20540" "Revista" => array:6 [ "tituloSerie" => "J Med Virol" "fecha" => "2006" "volumen" => "78" "paginaInicial" => "305" "paginaFinal" => "310" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16372293" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatitis B and C in children." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Hsu EK" 1 => "Murray K" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Nat Clin Pract Gastroent Hepatol" "fecha" => "2008" "paginaInicial" => "1" "paginaFinal" => "10" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clin Infect Dis" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "European Pediatric Hepatitis C Virus Network: Three broad modalities in the natural history of vertically acquired hepatitis C virus infection." "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "fecha" => "2005" "volumen" => "41" "paginaInicial" => "45" "paginaFinal" => "51" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chronic hepatitis C Virus Infection in Children." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Mohan N" 1 => "GonzÁlez Peralta RP" 2 => "Fujisawa T" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "JPGN" "fecha" => "2010" "volumen" => "50" "paginaInicial" => "23" "paginaFinal" => "131" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white childrens." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Jara P" 1 => "Resti M" 2 => "Hierro L" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/345908" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2003" "volumen" => "36" "paginaInicial" => "275" "paginaFinal" => "280" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12539067" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of hepatitis C in children." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Jara P" 1 => "Hierro L" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/egh.09.71" "Revista" => array:7 [ "tituloSerie" => "Expert Rev. Gastroenterol. Hepatol" "fecha" => "2010" "volumen" => "4" "numero" => "1" "paginaInicial" => "1" "paginaFinal" => "12" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20136583" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety, efficacy and pharmacokinetics of peginterferon? 2a (40 Kd) in children with chronic hepatitis C." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Schwarz KB" 1 => "Mohan P" 2 => "Narkewicz MR" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Ped Gastroenterol and Nutr" "fecha" => "2006" "volumen" => "43" "paginaInicial" => "499" "paginaFinal" => "505" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatitis B virus and hepatitis C virus infection in children." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Tovo PA" 1 => "Lazier L" 2 => "Versace A" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Curr Opin Infect Dis" "fecha" => "2005" "volumen" => "18" "paginaInicial" => "261" "paginaFinal" => "266" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15864105" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An analysis of published trials of interferon monotherapy in children with chronic hepatitis C." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Jacobson KR" 1 => "Murray K" 2 => "Zellos A" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Pediatr Gastroenterol Nutr" "fecha" => "2002" "volumen" => "4" "paginaInicial" => "52" "paginaFinal" => "58" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3981369" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "On behalf of the Trend Hepatitis C Study Group. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Neal KR" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/gut.2006.113217" "Revista" => array:6 [ "tituloSerie" => "Gut" "fecha" => "2007" "volumen" => "56" "paginaInicial" => "1098" "paginaFinal" => "1104" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17344277" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Soga K" 1 => "Shibasaki K" 2 => "Aoyagi Y" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:8 [ "tituloSerie" => "Hepatogastroenterology" "fecha" => "2005" "volumen" => "52" "numero" => "64" "paginaInicial" => "1154" "paginaFinal" => "1158" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16001651" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0211139X18300866" "estado" => "S300" "issn" => "0211139X" ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Peginterferon alf-2b plus ribavirina treatment in children and adolescents with chronic hepatitis C." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Wirth S" 1 => "Pieper-Boustani H" 2 => "Lang T" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.20661" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2005" "volumen" => "41" "paginaInicial" => "1013" "paginaFinal" => "1018" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15793840" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pathology of Chronic Hepatitis C in Children: Liver Biopsy Findings in the Peds-C Trial." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:4 [ 0 => "Goodman ZD" 1 => "Makhlouf H" 2 => "Liu L" 3 => "Balistreri W" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.22094" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2008" "volumen" => "47" "paginaInicial" => "836" "paginaFinal" => "843" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18167062" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time?" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "Guido M" 1 => "Bortolotti F" 2 => "Leandro G" 3 => "Jara P" 4 => "Hierro L" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "A J Gastroenterol" "fecha" => "2003" "volumen" => "98" "paginaInicial" => "660" "paginaFinal" => "663" ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatitis B and C in children: Current treatment and future strategies." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Scott AE" 1 => "Maureen MJ" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cld.2005.10.005" "Revista" => array:6 [ "tituloSerie" => "Clin Liver Dis" "fecha" => "2006" "volumen" => "10" "paginaInicial" => "133" "paginaFinal" => "148" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16376798" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and Safety of Peg-IFN a 2b and ribavirin in combination therapy in children with chronic hepatitis C, 2008." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Jara P" 1 => "Hierro L" 2 => "De la Vega A" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Pediatr Infec Dis J" "fecha" => "2008" "volumen" => "27" "paginaInicial" => "142" "paginaFinal" => "148" ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:4 [ 0 => "Whirth S" 1 => "Ribes-Koninckx C" 2 => "Calzadó MA" 3 => "Flavia Bortolotti" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2009.12.018" "Revista" => array:7 [ "tituloSerie" => "J Hepatol" "fecha" => "2010" "volumen" => "52" "numero" => "4" "paginaInicial" => "472" "paginaFinal" => "474" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20185196" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/16652681/00000009000000S1/v1_201906221034/S1665268119317326/v1_201906221034/en/main.assets" "Apartado" => array:4 [ "identificador" => "78189" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Module XIV" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/16652681/00000009000000S1/v1_201906221034/S1665268119317326/v1_201906221034/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119317326?idApp=UINPBA00004N"]

Statistics

Marcela Galoppo

Corresponding author

mgaloppo@hotmail.com
crisgaloppo@gmail.com

Correspondence and reprint request:

, Cristina Galoppo*

* Pediatric Hepatologist

Read

2039

Times
was read the article

406

Total PDF

1633

Total HTML

Share statistics

 array:24 [
  "pii" => "S1665268119317326"
  "issn" => "16652681"
  "doi" => "10.1016/S1665-2681(19)31732-6"
  "estado" => "S300"
  "fechaPublicacion" => "2010-01-01"
  "aid" => "71394"
  "copyright" => "Fundaci&#243;n Cl&#237;nica M&#233;dica Sur&#44; A&#46;C&#46;"
  "copyrightAnyo" => "2010"
  "documento" => "article"
  "crossmark" => 0
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "fla"
  "cita" => "Ann Hepatol. 2010;9 Supl 1:S98-S102"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 52
    "formatos" => array:3 [
      "EPUB" => 12
      "HTML" => 20
      "PDF" => 20
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S1665268119317338"
    "issn" => "16652681"
    "doi" => "10.1016/S1665-2681(19)31733-8"
    "estado" => "S300"
    "fechaPublicacion" => "2010-01-01"
    "aid" => "71395"
    "copyright" => "Fundaci&#243;n Cl&#237;nica M&#233;dica Sur&#44; A&#46;C&#46;"
    "documento" => "article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "Ann Hepatol. 2010;9 Supl 1:S103-6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 55
      "formatos" => array:3 [
        "EPUB" => 16
        "HTML" => 17
        "PDF" => 22
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "Treatment of HCV infected patients and renal disease"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "S103"
          "paginaFinal" => "S106"
        ]
      ]
      "contieneResumen" => array:1 [
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "David Kershenobich"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "David"
              "apellidos" => "Kershenobich"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119317338?idApp=UINPBA00004N"
    "url" => "/16652681/00000009000000S1/v1_201906221034/S1665268119317338/v1_201906221034/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S1665268119317314"
    "issn" => "16652681"
    "doi" => "10.1016/S1665-2681(19)31731-4"
    "estado" => "S300"
    "fechaPublicacion" => "2010-01-01"
    "aid" => "71393"
    "copyright" => "Fundaci&#243;n Cl&#237;nica M&#233;dica Sur&#44; A&#46;C&#46;"
    "documento" => "article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "Ann Hepatol. 2010;9 Supl 1:S92-7"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 56
      "formatos" => array:3 [
        "EPUB" => 10
        "HTML" => 21
        "PDF" => 25
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "The management of HCV-infected pregnant women"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "S92"
          "paginaFinal" => "S97"
        ]
      ]
      "contieneResumen" => array:1 [
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Guillermo Valladares, Maria H&#46; Sjogren, Alfonso Chacaltana"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Guillermo"
              "apellidos" => "Valladares"
            ]
            1 => array:2 [
              "nombre" => "Maria H&#46;"
              "apellidos" => "Sjogren"
            ]
            2 => array:2 [
              "nombre" => "Alfonso"
              "apellidos" => "Chacaltana"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119317314?idApp=UINPBA00004N"
    "url" => "/16652681/00000009000000S1/v1_201906221034/S1665268119317314/v1_201906221034/en/main.assets"
  ]
  "en" => array:16 [
    "idiomaDefecto" => true
    "titulo" => "Management of hepatitis C virus infection in childhood"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "S98"
        "paginaFinal" => "S102"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Marcela Galoppo, Cristina Galoppo"
        "autores" => array:2 [
          0 => array:4 [
            "nombre" => "Marcela"
            "apellidos" => "Galoppo"
            "email" => array:2 [
              0 => "mgaloppo@hotmail.com"
              1 => "crisgaloppo@gmail.com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "&#42;"
                "identificador" => "aff1"
              ]
              1 => array:2 [
                "etiqueta" => "&#42;"
                "identificador" => "cor1"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Cristina"
            "apellidos" => "Galoppo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "&#42;"
                "identificador" => "aff1"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:3 [
            "entidad" => "Pediatric Hepatologist"
            "etiqueta" => "&#42;"
            "identificador" => "aff1"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor1"
            "etiqueta" => "&#42;"
            "correspondencia" => "Correspondence and reprint request&#58;"
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Introduction</span><p id="p0005" class="elsevierStylePara elsevierViewall">Infection with hepatitis C virus &#40;HCV&#41; is a worldwide health problem with more than 170 million infected individuals&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> There is geographic variation in the incidence and prevalence of this infection&#46;</p><p id="p0010" class="elsevierStylePara elsevierViewall">HCV antibodies in children are between 0&#46;2&#37; and 0&#46;4&#37;&#44; with an age-dependent increase in seropreva-lence &#40;0&#46;2&#37; for children aged 6-11 years and 0&#46;4&#37; for children aged 12-19 years&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> Since 1992 almost all infections occurred through vertical transmission from an infected mother to her newborn infant&#46;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="p0015" class="elsevierStylePara elsevierViewall">A recent report of Italy showed 40&#37; reduction in the number of infected children seen from 2000 to 2004 by comparison with the previous 5 years&#46; The low prevalence of HCV infection in children can be explained by the disappearance of post transfusion hepatitis in developed countries and the low efficacy of mother-to-child transmission&#44; which has become the principal source of infection in the pediatric set-ting&#46;<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5</span></a><span class="elsevierStyleSup">-</span><a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a></p><p id="p0020" class="elsevierStylePara elsevierViewall">Natural history of HCV infection in children is not yet well defined&#59; most children are asymptomatic and may remain so for decades&#46; Diagnosis is generally made screening risk factor patients&#44; elevated aminotransferases in routine tests and household HCV infected adults&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p><p id="p0025" class="elsevierStylePara elsevierViewall">Treatment strategies in adults have had a significant impact on the management of children with HCV chronic infection&#46; All efforts now are towards to early diagnosis&#44; safety and efficacy treatment&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Epidemiology and Risk of Transmission</span><p id="p0030" class="elsevierStylePara elsevierViewall">After blood donor screening began in the 1990&#8217;s&#44; the risk of contracting HCV from blood and derivatives became extremely low in developed countries&#44; in-travenous drug abuse and high-risk sexual behavior are maintaining the reservoir of infection in adults and groups of adolescents&#46; Transmission through in-fected blood products&#44; however&#44; remains a risk in countries where strict recommendations for screening blood products are not reliably adhered to&#46; Horizontal transmission for family members is uncommon&#46;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="p0035" class="elsevierStylePara elsevierViewall">In children vertical transmission is responsible for most &#8220;new infections&#8221;&#44; however&#44; has an efficiency of only about 5&#37;&#46;<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6</span></a><span class="elsevierStyleSup">-</span><a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p><p id="p0040" class="elsevierStylePara elsevierViewall">Risk of maternal-infant transmission is increased &#40;up to 22&#37;&#41; by level of maternal HCV viral load such as HIV co infection&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a><span class="elsevierStyleSup">-</span><a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a></p><p id="p0045" class="elsevierStylePara elsevierViewall">Vertical transmission is almost always confined to women who have detectable HCV RNA&#46; There is an extremely low risk of transmission with undetec-table or intermittent viremia&#44; even though the risk of infection in this clinical situation is as low as 0&#46;3&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a><span class="elsevierStyleSup">-</span><a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p><p id="p0050" class="elsevierStylePara elsevierViewall">Presumably&#44; both intrauterine and intrapartum infections occur&#46; The mode of delivery does not affect risk of HCV transmission&#46; Membrane ruptures longer than six hours and internal fetal monitoring were associated with an increased risk of transmission&#46; Current recommendations are that women with HCV without HIV co-infection can be advised to breast feed&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a></p><p id="p0055" class="elsevierStylePara elsevierViewall">Recent studies showed that girls were twice as likely to be infected as boys&#46; This finding&#44; may reflects differences between males and females in hormonal or genetic susceptibility or immunological response to infections&#46;<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9</span></a><span class="elsevierStyleSup">-</span><a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a></p><p id="p0060" class="elsevierStylePara elsevierViewall">Diagnoses of HCV infection in exposed infants is hampered by passive transfer of maternal antibodies during pregnancy persisting up to 13 to 18 months of life&#46;<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> HCVRNA polymerase chain reaction &#40;PCR&#41; testing is highly specific&#44; but its sensitivity is low at birth and in the first days of life &#40;22&#37;&#41; while it increases at one month of age and thereafter &#40;&#62; 75&#37;&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9</span></a><span class="elsevierStyleSup">-</span><a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a></p><p id="p0065" class="elsevierStylePara elsevierViewall">A child born to a seropositive mother is conside-rer to be infected if serum HCVRNA is detectable in at least two separate determinations between 2-6 months and whit persistence of anti-HCV antibodies after the first year of life&#46; Chronic infection is defined as the persistence of HCV RNA for at least six months and resolution is determined by the persistent disappearance of HCVRNA&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Natural History and Diagnosis</span><p id="p0070" class="elsevierStylePara elsevierViewall">Most infected individuals &#40;60-80&#37;&#41;&#44; regardless of their age at infection&#44; become chronically infected with HCV&#46;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a></p><p id="p0075" class="elsevierStylePara elsevierViewall">Spontaneous resolution in children appears to be infrequent&#58; in three large series&#44; including vertical and horizontal acquisition&#44; HCV clearance occurred in 5&#46;6-10&#37;&#44;<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> children infected with genotype 3 &#40;81&#37; of whom were vertically infected&#41; had the highest rate of viral clearance &#40;22&#37;&#41; compared to other genotypes&#46;<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a></p><p id="p0080" class="elsevierStylePara elsevierViewall">In 266 vertically HCV infected children&#44; 17&#37; showed viral clearance by 2&#44; 24&#37; by 3&#44; and 25&#37; by 5 years of age &#40;median age 14&#46; 9 m&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a></p><p id="p0085" class="elsevierStylePara elsevierViewall">Transfusion acquired infection have a higher chance of spontaneous clearance than vertical acquisition&#46; HCV genotype&#44; viral load and immunoto-lerance in young infants&#44; were proposed to influence viral resolution&#46;<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9</span></a><span class="elsevierStyleSup">-</span><a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a></p><p id="p0090" class="elsevierStylePara elsevierViewall">Once chronicity is established&#44; such as in older children&#44; serological and histological features seem to be independent of the source and time of infec-tion&#46;<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> Illness is generally asymptomatic and characterized by a bening course during the first two decades of life&#46; Advanced liver disease is rare during childhood and there are no reports of acute liver failure in HCV pediatric infected patient&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> Clinical symptoms are mild and nonspecific in only 20&#37; of cases during early childhood&#46; Hepatomegaly is present in 10&#37; of infected children&#46;</p><p id="p0095" class="elsevierStylePara elsevierViewall">HCV-associated cryoglobulinemia&#44; vasculitis and porphyria cutanea tarda are not reported in chil-dren&#46;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a></p><p id="p0100" class="elsevierStylePara elsevierViewall">Aminotransferases remains usually normal or mildly abnormal levels but it is not a reliable indicator of abscense of hepatic injury&#46;<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">17</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a></p><p id="p0105" class="elsevierStylePara elsevierViewall">Positive HCV antibody implicate that patient has been exposed to the virus &#40;EIA test&#41;&#46; Anti-HCV antibodies may be undetectable during first few weeks after HCV exposure or in immunocompromised pa-tients&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a></p><p id="p0110" class="elsevierStylePara elsevierViewall">To discriminate between active or resolved HCV viral infection it is necessary to perform HCV RNA &#40;PCR&#41;&#46; HCV RNA PCR may be intermittently negative&#46;</p><p id="p0115" class="elsevierStylePara elsevierViewall">HCV genotype and HCV-RNA viral load provide useful information for predicting response to therapy&#46; HCV genotype is also used to determine the length of therapy&#46;<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8</span></a><span class="elsevierStyleSup">-</span><a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a></p><p id="p0120" class="elsevierStylePara elsevierViewall">Liver biopsy assess degree of liver injury and exclude concurrent diseases specially in children with normal transaminases who are being considered for treatment&#46;<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8</span></a><span class="elsevierStyleSup">-</span><a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> Histological picture is similar to those of adults&#46; Necrotic inflammation and fibrosis are usually milder&#44; though liver damage is greater in older patients and progression to cirrhosis has been noted&#46;<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Treatment</span><p id="p0125" class="elsevierStylePara elsevierViewall">HCV chronic infection is slow progressive in childhood therefore&#8217; there is no uniform consensus about timing for treatment&#46; Progression of fibrosis seems to be a function of infection duration&#8217; when no other risk factors for liver damage are present&#46; HCV cirrhosis and its complications in adulthood and universal recurrence in post transplant recipients justify medical decision in favor of treatment&#46; Therefore&#44; children are ideal candidates for treatment&#46; The shorter the duration of infection with mild histological disease&#44; the better the response to treatment&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">18</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a></p><p id="p0130" class="elsevierStylePara elsevierViewall">A review of published trials with Interferon &#40;IFN&#41; monotherapy in 105 children showed average an end-of-treatment response &#40;ETR&#41; of 54&#37; and sustained virological response &#40;SVR&#41; of 36&#37;&#46; The SVR in genotype 1 was 27&#37; versus 70&#37; for non genotype 1 &#40;p&#58; 0&#46;001&#41;&#46; The SVR rates were higher than those reported in adults&#46;<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a></p><p id="p0135" class="elsevierStylePara elsevierViewall">Different trials with combination therapy were done and others are in progress <a class="elsevierStyleCrossRef" href="#t0005">&#40;Table 1&#41;</a>&#46;</p><elsevierMultimedia ident="t0005"></elsevierMultimedia></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Primary Goal of Treatment</span><p id="p0140" class="elsevierStylePara elsevierViewall">Clearance viral infection &#40;HCV RNA non detectable in serum&#41;&#44; regression or delay in liver fibrosis&#44; prevention of chronic liver disease and development of HCC and improve quality of life&#46;</p><p id="p0145" class="elsevierStylePara elsevierViewall">Benefits of treatment are not restricted to biochemical&#44; histologic or virologic response&#58; quality of life&#44; risk of hepatocellular carcinoma&#44; and mortality risk may be favorably affected by treatment&#44; even in the absence of sustained viral response&#46;<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">18</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Considering Treatment</span><p id="p0150" class="elsevierStylePara elsevierViewall">IFN alfa is recognized as the drug approved for hepatitis C treatment in pediatric population&#46; As in adults&#44; combination therapy with IFN&#945; or pegylated IFN&#945; and ribavirin in children under clinical trials&#44; support its efficacy in sustained virological response &#40;SVR&#41; compared with IFN&#945; alone&#46; Recently&#44; the US FDA and EMEA have approved combined pegylated-IFN&#945;2b plus ribavirin treatment for children&#46;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> Principal advantage of PEG-IFN&#945; is the extended serum half-life conferred by pegylation of the IFN molecule&#44; which confers a once-weekly administration and improved efficacy and a safety profile similar to that of IFN&#945;&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a></p><p id="p0155" class="elsevierStylePara elsevierViewall">Treatment should be considered in children between 3 to 18 years old&#44; anti HCV &#40;&#43;&#41;&#44; HCVRNA &#40;&#43;&#41; for at least 6 months and normal or abnormal ALT&#46;</p><p id="p0160" class="elsevierStylePara elsevierViewall">Patients are excluded if they have comorbid medical conditions that could compromise the safety&#44; efficacy and tolerability of drugs&#46;<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a></p><p id="p0165" class="elsevierStylePara elsevierViewall">Liver biopsy remains the gold standard for assessing the severity of inflammation and fibrosis&#44; and rule out concurrent diseases particularly in children whit normal liver tests&#46; Inflammation and fibrosis are less common than in adults but significant fibro-sis and cirrhosis may develop during childhood&#46; In a series of 112 pediatric patients with chronic hepatitis C the degree of fibrosis correlated with age and duration of infection&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a></p><p id="p0170" class="elsevierStylePara elsevierViewall">There are different opinions about performing liver biopsy in genotypes 2 and 3 whose sustained vi-rological response rates exceed 80&#37;&#46;<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">18</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a></p><p id="p0175" class="elsevierStylePara elsevierViewall">HCV genotype should be identify to establish treatment duration and probability of response&#46; For genotypes 1 and 4&#44; therapy is recommended for at least 48 weeks&#44; overall SVR is 50&#37;&#46; Genotypes 2 and 3 should be treated only for 24 weeks&#59; overall SVR is 83-100&#37;&#46;<a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">18</span></a><span class="elsevierStyleSup">-</span><a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a></p><p id="p0180" class="elsevierStylePara elsevierViewall">Viral load is necessary to evaluate virological response during treatment&#46;</p><p id="p0185" class="elsevierStylePara elsevierViewall">Treatment objective is clearance of HCVRNA below the detection limit of PCR technique employed &#40;30-50IU&#47;mL&#41;&#46; Then&#44; therapy should continue in order to eradicate infection in the liver&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Treatment Schedule and Monitoring</span><p id="p0190" class="elsevierStylePara elsevierViewall">The dose of IFN&#945; monotherapy is 3 MIU&#47;m<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> sub-cutaneously 3 times a week&#46;<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a></p><p id="p0195" class="elsevierStylePara elsevierViewall">PEG-IFN&#945;-2b &#40;60 <span class="elsevierStyleItalic">&#956;</span>g&#47;m<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a>&#47;week or 1-1&#46;5 <span class="elsevierStyleItalic">&#956;</span>g&#47;kg&#47;wk&#41; or &#945;2a &#40;100 <span class="elsevierStyleItalic">&#956;</span>g&#47;m<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a>&#47;week&#41; subcutaneously plus Riba-virina &#40;15 mg&#47;kg&#47;day&#41; twice orally is used in combination therapy&#46;<a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">18</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">23</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">26</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">29</span></a></p><p id="p0200" class="elsevierStylePara elsevierViewall">Adverse events are common during treatment&#44; particularly transient &#8220;flu-like syndrome&#8221;&#44; leukope-nia and neutropenia related to IFN&#46; Although rare&#44; depression and suicidal ideation attempt occurs in treated children&#46; Antithyroid antibodies are common and clinical thyroid disease occurs but rarely becomes permanent&#46;<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">18</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">26</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">29</span></a></p><p id="p0205" class="elsevierStylePara elsevierViewall">The most common adverse effect of ribavirin is a reversible hemolytic anemia&#46; Ribavirin is also known to be teratogenic&#46;<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">18</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">26</span></a><span class="elsevierStyleSup">&#44;</span><a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">29</span></a></p><p id="p0210" class="elsevierStylePara elsevierViewall">Liver&#44; hematology&#44; thyroid and other routine tests should be periodically done in order to detect adverse events for evaluate eventually reduction or interruption medication&#46; HCV RNA titers are measured at 4&#44; 12&#44; 24&#44; 36 and 48 weeks&#44; and every 12 weeks for another 6 months after the end of treatment&#46;</p><p id="p0215" class="elsevierStylePara elsevierViewall">Diagnosis and treatment strategies in children should be prescribe and supervise by pediatric hepa-tologist&#46;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:10 [
        0 => array:3 [
          "identificador" => "xres1210341"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abs0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1126758"
          "titulo" => "Key words"
        ]
        2 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        3 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Epidemiology and Risk of Transmission"
        ]
        4 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Natural History and Diagnosis"
        ]
        5 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Treatment"
        ]
        6 => array:2 [
          "identificador" => "sec0025"
          "titulo" => "Primary Goal of Treatment"
        ]
        7 => array:2 [
          "identificador" => "sec0030"
          "titulo" => "Considering Treatment"
        ]
        8 => array:2 [
          "identificador" => "sec0035"
          "titulo" => "Treatment Schedule and Monitoring"
        ]
        9 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2010-03-20"
    "fechaAceptado" => "2010-04-20"
    "PalabrasClave" => array:1 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Key words"
          "identificador" => "xpalclavsec1126758"
          "palabras" => array:6 [
            0 => "Children"
            1 => "Chronic hepatitis C"
            2 => "Hepatitis C virus"
            3 => "IFN"
            4 => "Pegylated IFN"
            5 => "Ribavirin"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:1 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abs0005" class="elsevierStyleSection elsevierViewall"><p id="sp0010" class="elsevierStyleSimplePara elsevierViewall">Infection with hepatitis C virus &#40;HCV&#41; is a worldwide health problem with more than 170 million infected individuals&#46; In children&#44; since 1992 almost all infections occurred through vertical transmission from an infected mother to her newborn infant&#46; Natural history of HCV infection in children is not yet well defined&#44; most children are asymptomatic and may remain so for decades&#46; Most infected individuals &#40;60-80&#37;&#41;&#44; regardless of their age at infection&#44; become chronically infected with HCV&#46; Spontaneous resolution in children appears to be infrequent&#46; Positive HCV antibody implicate that patient has been exposed to the virus &#40;EIA test&#41;&#46; To discriminate between active or resolved HCV viral infection it is necessary to perform HCV RNA &#40;PCR&#41;&#46; Liver biopsy assess degree of liver injury and exclude concurrent diseases&#46; HCV chronic infection is slow progressive in childhood&#46; Progression of fibrosis seems to be a function of infection duration&#46; Treatment objective is clearance of HCVRNA&#46; IFN&#945; is recognized as the drug approved for hepatitis C treatment in pediatric population&#46; Combination therapy with IFN&#945; or pegylated IFN&#945; plus ribavirin is recently approved by US FDA and EMEA and clinical trials are in progress&#46;</p></span>"
      ]
    ]
    "multimedia" => array:1 [
      0 => array:7 [
        "identificador" => "t0005"
        "etiqueta" => "<span class="elsevierStyleBold">Table 1&#46;</span>"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="np0005" class="elsevierStyleSimplePara elsevierViewall">HCV &#61; hepatitis C virus&#59; IFN &#61; interferon&#59; PEGIFN &#61; pegylated interferon&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="middle" scope="col">Study&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="3" align="center" valign="middle" scope="col">Sustained response<a class="elsevierStyleCrossRef" href="#t1fn2">&#42;&#42;</a> &#40;&#37;&#41;</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">N&#176; Studied<a class="elsevierStyleCrossRef" href="#t1fn1">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">Treatment regimen&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">All Types&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">HCV type 1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="center" valign="middle" scope="col">HCV type 2&#47;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="middle">Gonz&#225;lez-Peralta&#44; <span class="elsevierStyleBold"><span class="elsevierStyleItalic">et al&#46;</span></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">IFN-ribavirin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">64&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">40&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">100&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="middle">Strickland&#44; <span class="elsevierStyleBold"><span class="elsevierStyleItalic">et al&#46;</span></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">IFN-ribavirin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">50&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">50&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">N&#47;A <a class="elsevierStyleCrossRef" href="#t1fn3">&#42;&#42;&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="middle">Bruix and Sherman&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">41&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">IFN-ribavirin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">61&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">53&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">100&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="middle">Peters and Terrault&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">118&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">IFN-ribavirin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">36&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">84&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="middle">Sasaki&#44; <span class="elsevierStyleBold"><span class="elsevierStyleItalic">et al&#46;</span></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">PEGIFN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">38&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">38&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">N&#47;A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="middle">Ni&#44; <span class="elsevierStyleBold"><span class="elsevierStyleItalic">et al&#46;</span></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">59&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">PEGIFN-ribavirin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">59&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">50&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">100&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="middle">lorio&#44; <span class="elsevierStyleBold"><span class="elsevierStyleItalic">et al&#46;</span></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">30&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">PEGIFN-ribavirin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">50&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">100&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="middle">Fried&#44; <span class="elsevierStyleBold"><span class="elsevierStyleItalic">et al&#46;</span></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">107&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">PEGIFN-ribavirin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">65<a class="elsevierStyleCrossRef" href="#t1fn3">&#42;&#42;&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">53<a class="elsevierStyleCrossRef" href="#t1fn4">&#42;&#42;&#42;&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">93<a class="elsevierStyleCrossRef" href="#t1fn4">&#42;&#42;&#42;&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="middle">Di Bisceglie&#44; <span class="elsevierStyleBold"><span class="elsevierStyleItalic">et al&#46;</span></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">55&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">PEGIFN-ribavirin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">53&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">47<a class="elsevierStyleCrossRef" href="#t1fn4">&#42;&#42;&#42;&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">80<a class="elsevierStyleCrossRef" href="#t1fn4">&#42;&#42;&#42;&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="middle">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">59&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">PEGIFN-alone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">18<a class="elsevierStyleCrossRef" href="#t1fn4">&#42;&#42;&#42;&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">36<a class="elsevierStyleCrossRef" href="#t1fn4">&#42;&#42;&#42;&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="middle">Jara&#44; <span class="elsevierStyleBold"><span class="elsevierStyleItalic">et al&#46;</span></span><a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">30</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">30&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">PEGIFN-ribavirin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">50&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">44&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">100&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="middle">Wirth&#44; <span class="elsevierStyleBold"><span class="elsevierStyleItalic">et al&#46;</span></span><a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">31</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">107&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">PEGIFN-ribavirin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">65&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">53&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="center" valign="middle">93&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2066308.png"
              ]
            ]
          ]
          "notaPie" => array:4 [
            0 => array:3 [
              "identificador" => "t1fn1"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Number of HCV-infected patients treated in the studies cited&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "t1fn2"
              "etiqueta" => "&#42;&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Undetectable serum HCV RNA 6 months after stopping treatment&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "t1fn3"
              "etiqueta" => "&#42;&#42;&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Sustained response was noted in 4 of 5 &#40;80&#37;&#41; of enrolled children with HCV genotype 4&#46;</p>"
            ]
            3 => array:3 [
              "identificador" => "t1fn4"
              "etiqueta" => "&#42;&#42;&#42;&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Only percentages presented in preliminary report &#40;abstract&#41;&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="sp0005" class="elsevierStyleSimplePara elsevierViewall">Selected Treatment trials in children with chronic HCV infection&#46;&#40;<span class="elsevierStyleSup">18 modif</span>&#41;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bs0005"
          "bibliografiaReferencia" => array:31 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global epidemiology of Hepatitis C virus Infection&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "Shepard CW"
                            1 => "Finelli L"
                            2 => "Alter MJ"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Lancet Infect Dis"
                        "fecha" => "2005"
                        "volumen" => "5"
                        "paginaInicial" => "556"
                        "paginaFinal" => "558"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board&#44; Antwerp&#44; Belgium&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "World Health Organization&#46;Global Surveillance an Control of Hepatitis C&#46;"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Viral Hepatitis"
                        "fecha" => "1999"
                        "volumen" => "6"
                        "paginaInicial" => "35"
                        "paginaFinal" => "47"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The prevalence of hepatitis C virus infection in the United States&#44; 1988-1994&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "Alter MD"
                            1 => "Kruszon-Moran D"
                            2 => "Nainan OV"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJM199908193410802"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "1999"
                        "volumen" => "341"
                        "paginaInicial" => "556"
                        "paginaFinal" => "562"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10451460"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Management Strategies for Hepatitis C Virus Infection in Children&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Davison SM"
                            1 => "Kelly DA"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Pediatr Drugs"
                        "fecha" => "2008"
                        "volumen" => "10"
                        "numero" => "6"
                        "paginaInicial" => "357"
                        "paginaFinal" => "365"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatitis C virus &#40;HCV genotypes in 373 Italian children with HCV infection&#58; changing distribution and correlation with clinical features and outcome&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "Bortolotti F"
                            1 => "Resti M"
                            2 => "Marcellini M"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/gut.2004.053744"
                      "Revista" => array:7 [
                        "tituloSerie" => "Gut"
                        "fecha" => "2005"
                        "volumen" => "54"
                        "paginaInicial" => "852"
                        "paginaFinal" => "857"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15888796"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0211139X17301270"
                          "estado" => "S300"
                          "issn" => "0211139X"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Italian Observatory for HCV Infection and Hepatitis C in Children&#46; Epidemiological profile of 806 Italian Children with hepatitis C virus infection over a 15-year period&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "Bortolotti F"
                            1 => "Jorio R"
                            2 => "Resti M"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2006.12.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol"
                        "fecha" => "2007"
                        "volumen" => "46"
                        "paginaInicial" => "783"
                        "paginaFinal" => "790"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17321633"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Chronic viral hepatitis in children&#58; any role for the pathologist&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Guido M"
                            1 => "Bortolotti F"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/gut.2007.139410"
                      "Revista" => array:7 [
                        "tituloSerie" => "Gut"
                        "fecha" => "2008"
                        "volumen" => "57"
                        "paginaInicial" => "873"
                        "paginaFinal" => "877"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18559378"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S147330991730405X"
                          "estado" => "S300"
                          "issn" => "14733099"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Organizado por la Aso-ciaci&#243;n Argentina para el Estudio de las Enfermedades del Higado &#40;AAEEH&#41;&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "Consenso Argentino de Hepatitis C&#46;"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Buenos Aires"
                        "fecha" => "2007"
                        "paginaInicial" => "53"
                        "paginaFinal" => "69"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Perinatal hepatitis C virus infection&#58; Diagnosis and management&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Davison SM"
                            1 => "Mieli-Vergani G"
                            2 => "Sira J"
                            3 => "Kelly DA"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/adc.2005.081877"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Dis Child"
                        "fecha" => "2006"
                        "volumen" => "91"
                        "paginaInicial" => "781"
                        "paginaFinal" => "785"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16923861"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Committee of Hepatology of the Italian Society of Pediatric Gastroenteroly and Hepatology&#46; Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Resti M"
                            1 => "Bortolotti F"
                            2 => "Vajro P"
                            3 => "Maggiore G"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "Dig Liver Dis"
                        "fecha" => "2003"
                        "volumen" => "35"
                        "numero" => "7"
                        "paginaInicial" => "453"
                        "paginaFinal" => "457"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12870728"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of mode and delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "European Pediatric Hepatitis C Virus Network&#46;"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Obstet Ginaecol"
                        "fecha" => "2001"
                        "volumen" => "108"
                        "paginaInicial" => "371"
                        "paginaFinal" => "377"
                        "itemHostRev" => array:3 [
                          "pii" => "S0211139X16301354"
                          "estado" => "S300"
                          "issn" => "0211139X"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk Factors for prenatal transmission of hepatitis C virus &#40;HCV&#41; and the natural history of HCV infection acquired in infancy&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "Mast EE"
                            1 => "Hwang LY"
                            2 => "Seto DSY"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1086/497701"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Infect Dis"
                        "fecha" => "2005"
                        "volumen" => "192"
                        "paginaInicial" => "1880"
                        "paginaFinal" => "1889"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16267758"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S138665321830074X"
                          "estado" => "S300"
                          "issn" => "13866532"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A significant sex-but not elective caesarean section-effect on mother-to-child-transmission of hepatitis C virus infection&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "European Pediatric Hepatitis C Virus Network&#46;"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1086/497695"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Infect Dis"
                        "fecha" => "2005"
                        "volumen" => "192"
                        "paginaInicial" => "1872"
                        "paginaFinal" => "1879"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16267757"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "European Pediatric HCV Network&#46; Excluding hepatitis C virus &#40;HCV&#41; infection by serology in young infants of HCV-infected mothers&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "England K"
                            1 => "Pembrey L"
                            2 => "Tovo TA"
                            3 => "Newell ML"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1651-2227.2005.tb01916.x"
                      "Revista" => array:7 [
                        "tituloSerie" => "Acta Paediatr"
                        "fecha" => "2005"
                        "volumen" => "94"
                        "paginaInicial" => "444"
                        "paginaFinal" => "450"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16092459"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0264410X16301700"
                          "estado" => "S300"
                          "issn" => "0264410X"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Accuracy of HCV-RNA PCR Test for Diagnosis of Exclusion of Vertically Acquired HCV Infection&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "Polywka S"
                            1 => "Pembrey L"
                            2 => "Tovo PA"
                            3 => "Newell ML"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/jmv.20540"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Med Virol"
                        "fecha" => "2006"
                        "volumen" => "78"
                        "paginaInicial" => "305"
                        "paginaFinal" => "310"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16372293"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatitis B and C in children&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Hsu EK"
                            1 => "Murray K"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Nat Clin Pract Gastroent Hepatol"
                        "fecha" => "2008"
                        "paginaInicial" => "1"
                        "paginaFinal" => "10"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clin Infect Dis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "European Pediatric Hepatitis C Virus Network&#58; Three broad modalities in the natural history of vertically acquired hepatitis C virus infection&#46;"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "fecha" => "2005"
                        "volumen" => "41"
                        "paginaInicial" => "45"
                        "paginaFinal" => "51"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Chronic hepatitis C Virus Infection in Children&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "Mohan N"
                            1 => "Gonz&#193;lez Peralta RP"
                            2 => "Fujisawa T"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "JPGN"
                        "fecha" => "2010"
                        "volumen" => "50"
                        "paginaInicial" => "23"
                        "paginaFinal" => "131"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Chronic hepatitis C virus infection in childhood&#58; clinical patterns and evolution in 224 white childrens&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "Jara P"
                            1 => "Resti M"
                            2 => "Hierro L"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1086/345908"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Infect Dis"
                        "fecha" => "2003"
                        "volumen" => "36"
                        "paginaInicial" => "275"
                        "paginaFinal" => "280"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12539067"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of hepatitis C in children&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Jara P"
                            1 => "Hierro L"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1586/egh.09.71"
                      "Revista" => array:7 [
                        "tituloSerie" => "Expert Rev&#46; Gastroenterol&#46; Hepatol"
                        "fecha" => "2010"
                        "volumen" => "4"
                        "numero" => "1"
                        "paginaInicial" => "1"
                        "paginaFinal" => "12"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20136583"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "21&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety&#44; efficacy and pharmacokinetics of peginterferon&#63; 2a &#40;40 Kd&#41; in children with chronic hepatitis C&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "Schwarz KB"
                            1 => "Mohan P"
                            2 => "Narkewicz MR"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Ped Gastroenterol and Nutr"
                        "fecha" => "2006"
                        "volumen" => "43"
                        "paginaInicial" => "499"
                        "paginaFinal" => "505"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "22&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatitis B virus and hepatitis C virus infection in children&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "Tovo PA"
                            1 => "Lazier L"
                            2 => "Versace A"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Opin Infect Dis"
                        "fecha" => "2005"
                        "volumen" => "18"
                        "paginaInicial" => "261"
                        "paginaFinal" => "266"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15864105"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "23&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "An analysis of published trials of interferon monotherapy in children with chronic hepatitis C&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "Jacobson KR"
                            1 => "Murray K"
                            2 => "Zellos A"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Pediatr Gastroenterol Nutr"
                        "fecha" => "2002"
                        "volumen" => "4"
                        "paginaInicial" => "52"
                        "paginaFinal" => "58"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3981369"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "24&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "On behalf of the Trend Hepatitis C Study Group&#46; Excess mortality rates in a cohort of patients infected with the hepatitis C virus&#58; a prospective study&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Neal KR"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/gut.2006.113217"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gut"
                        "fecha" => "2007"
                        "volumen" => "56"
                        "paginaInicial" => "1098"
                        "paginaFinal" => "1104"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17344277"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "25&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "Soga K"
                            1 => "Shibasaki K"
                            2 => "Aoyagi Y"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:8 [
                        "tituloSerie" => "Hepatogastroenterology"
                        "fecha" => "2005"
                        "volumen" => "52"
                        "numero" => "64"
                        "paginaInicial" => "1154"
                        "paginaFinal" => "1158"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16001651"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0211139X18300866"
                          "estado" => "S300"
                          "issn" => "0211139X"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "26&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Peginterferon alf-2b plus ribavirina treatment in children and adolescents with chronic hepatitis C&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "Wirth S"
                            1 => "Pieper-Boustani H"
                            2 => "Lang T"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.20661"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology"
                        "fecha" => "2005"
                        "volumen" => "41"
                        "paginaInicial" => "1013"
                        "paginaFinal" => "1018"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15793840"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "27&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pathology of Chronic Hepatitis C in Children&#58; Liver Biopsy Findings in the Peds-C Trial&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:4 [
                            0 => "Goodman ZD"
                            1 => "Makhlouf H"
                            2 => "Liu L"
                            3 => "Balistreri W"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.22094"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology"
                        "fecha" => "2008"
                        "volumen" => "47"
                        "paginaInicial" => "836"
                        "paginaFinal" => "843"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18167062"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "28&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Fibrosis in chronic hepatitis C acquired in infancy&#58; is it only a matter of time&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:5 [
                            0 => "Guido M"
                            1 => "Bortolotti F"
                            2 => "Leandro G"
                            3 => "Jara P"
                            4 => "Hierro L"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "A J Gastroenterol"
                        "fecha" => "2003"
                        "volumen" => "98"
                        "paginaInicial" => "660"
                        "paginaFinal" => "663"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "29&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatitis B and C in children&#58; Current treatment and future strategies&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Scott AE"
                            1 => "Maureen MJ"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cld.2005.10.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Liver Dis"
                        "fecha" => "2006"
                        "volumen" => "10"
                        "paginaInicial" => "133"
                        "paginaFinal" => "148"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16376798"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "30&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and Safety of Peg-IFN a 2b and ribavirin in combination therapy in children with chronic hepatitis C&#44; 2008&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "Jara P"
                            1 => "Hierro L"
                            2 => "De la Vega A"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Pediatr Infec Dis J"
                        "fecha" => "2008"
                        "volumen" => "27"
                        "paginaInicial" => "142"
                        "paginaFinal" => "148"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "31&#46;"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin&#46;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:4 [
                            0 => "Whirth S"
                            1 => "Ribes-Koninckx C"
                            2 => "Calzad&#243; MA"
                            3 => "Flavia Bortolotti"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2009.12.018"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Hepatol"
                        "fecha" => "2010"
                        "volumen" => "52"
                        "numero" => "4"
                        "paginaInicial" => "472"
                        "paginaFinal" => "474"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20185196"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/16652681/00000009000000S1/v1_201906221034/S1665268119317326/v1_201906221034/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "78189"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Module XIV"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/16652681/00000009000000S1/v1_201906221034/S1665268119317326/v1_201906221034/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119317326?idApp=UINPBA00004N"
]

Article information

ISSN: 16652681
Original language: English

DOI:10.1016/S1665-2681(19)31732-6

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	7	0	7
2024 October	44	3	47
2024 September	62	5	67
2024 August	43	9	52
2024 July	56	6	62
2024 June	36	4	40
2024 May	42	7	49
2024 April	53	9	62
2024 March	50	4	54
2024 February	55	9	64
2024 January	81	13	94
2023 December	72	13	85
2023 November	81	10	91
2023 October	85	11	96
2023 September	62	11	73
2023 August	74	4	78
2023 July	62	12	74
2023 June	62	8	70
2023 May	71	10	81
2023 April	16	4	20
2023 March	26	0	26
2023 February	14	8	22
2023 January	33	7	40
2022 December	24	4	28
2022 November	29	6	35
2022 October	15	5	20
2022 September	24	8	32
2022 August	27	14	41
2022 July	13	6	19
2022 June	15	8	23
2022 May	23	9	32
2022 April	21	10	31
2022 March	16	5	21
2022 February	9	5	14
2022 January	13	3	16
2021 December	21	9	30
2021 November	15	10	25
2021 October	7	9	16
2021 September	7	9	16
2021 August	14	11	25
2021 July	17	7	24
2021 June	12	8	20
2021 May	10	9	19
2021 April	42	13	55
2021 March	9	3	12
2021 February	6	9	15
2021 January	5	6	11
2020 December	5	4	9
2020 November	1	4	5
2020 October	5	5	10
2020 September	4	3	7
2020 August	3	7	10
2020 July	4	1	5
2020 June	1	1	2
2020 May	5	4	9
2020 April	1	1	2
2020 March	2	2	4
2020 February	2	3	5
2020 January	1	0	1
2019 December	6	5	11
2019 November	3	0	3
2019 October	2	1	3
2019 September	3	1	4
2019 August	1	1	2
2019 July	2	4	6
2019 June	1	6	7

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter